BreukelenF. J. M. (van), BijvoteO. L. M., OosetromA. T. (van): Inhibition of osteolytic bone lesion by 3-amino-hydroxypropylidene-l,l-diphosphonates (ADP). Lancet, 1; 803–805 (1979).
2.
DouglasD. L., DuckworthT., RussellR. G. G., KanisJ. A., PrestonR. G., PrestonF. E., PrentonM. A., WoodheadJ. S.: Effect of dichloromethylene diphosphonate in Paget's disease of bone and hypercalcemia due to primary hyperparathyroidism or malignant disease. Lancet, 1; 1043–1047 (1980).
3.
ElomaaI., BlomqvistC., PorkkaL., SelanderK., KairentoA. L, Lamberg-AllardtC., HolmstromT., GrohnP.: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet, 1; 146–149 (1983).
4.
FrancisM. D., RussellR. G. G., FleishH.: Diphosphonate inhibit formation of calcium phosphate crystal in vitro and pathological calcification in vivo. Science, 165; 1264 (1969).
5.
GalaskoC. S. B.: Mechanism of bone destruction in the development of skeletal metastases. Nature, 263; 507–508 (1976).
6.
JungA., ChantraineA., DonathA., van OuwenallerC., TurnillD., MermillodB., KitlerM. E.: Use of dichloromethylene diphosphonate in metastatic bone disease. N. Engl. J. Med., 308; 1499–1501 (1983).
7.
MillerS. C., JoeW. S. S.: Ethane-1-hydroxy-1,1-diphosphonate (EHDP): Effects on incorporation and accumulation of osteoclast nuclei. Calcif. Tissue Res., 22; 243–252 (1977).
8.
MundyG. R., RaiszL. G., CooperR. A., SchechterG. P., SalmonS. E.: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med., 291; 1041–1046 (1974).
9.
RussellR. G. G., MuhlebauerR. C., WilliamsD. A., FleishH.: The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomized rats. Calcif. Tissue Res., 6; 183 (1970).
10.
SchenkR., MerzW. A., MuhlbauerR., RussellR. G. G., FleishH.: Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (C12MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif. Tissue Res., 11; 196 (1973).
11.
SeybertH. W.: Prostaglandins as mediators of hypercalcemia associated with certain type of cancer. N. Engl. J. Med., 293; 1978 (1975).
12.
SirisE. S., HymanG. A., CanfieldR. E.: Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Amer. J. Med., 74; 401–406 (1983).
13.
SirisE. S., ShermanW. R., BaquiranD. C., SchlattaresJ. P., OssermanE. F., CanfieldR. E.: Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N. Engl. J. Med., 302; 310–315 (1980).
